key: cord-0962811-l711g3w2
authors: Goletti, Delia; Petrone, Linda; Manissero, Davide; Bertoletti, Antonio; Rao, Sonia; Ndunda, Nduku; Sette, Alessandro; Nikolayevskyy, Vladyslav
title: The potential clinical utility of measuring SARS-CoV-2-specific T-cell responses
date: 2021-07-10
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.07.005
sha: 970ccc26e937cec4567b84afd433f8cc48d9c0d0
doc_id: 962811
cord_uid: l711g3w2

BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to SARS-CoV-2. While our understanding of the potential role of T-cell responses in the context of COVID-19 is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB).

Introduction 45 studies, as reviewed by Schmidt and Varga [2] , have shown that CD8+ T-cells are critical for 48 mediating viral clearance [3] [4] [5] , and memory CD8+ T-cells can provide protection against secondary 49 infections [6, 7] . Based on findings such as these, it is reasonable to hypothesise that induction of 50 both humoral and T-cell responses (including CD4+ and CD8+ T-cells) are required for an optimal 51 immune response to natural respiratory infection, and post-vaccination.

In the case of influenza A virus, strain-specific protection generally afforded by the humoral 53 immune response is complemented by virus-specific CD8+ and CD4+ T-cells that provide cross-54 reactive responses recognising different virus subtypes [8] . The same principle of a combined 55 humoral and cell-mediated response for optimal immunity may apply to SARS-CoV-2 infection, with 56 virus-specific CD4+ T-cells, among their other functions, likely serving critical roles in establishing 57 protective antibody responses [9] .

T-cell responses are also required for optimal immunity to bacterial respiratory pathogens.

For example, as initially demonstrated in murine models [10] , humoral immunity alone is not 

and non-survival [18] . Earlier induction of IFN-γ-secreting T-cells may also be a marker of better 84 prognosis [14, 15, 19] . These observations help to explain why T-cell count and clonal expansion of associated with increased survival and lower viral load [24] .

The quality of T-cell responses may also play an important role. Le Bert and colleagues noted 99 increased IFN-y and IL-2 production in asymptomatic patients compared with symptomatic patients, 

The longevity of T-cell immunity appears in line with antibody responses, suggesting a 107 durable immune response to natural SARS-CoV-2 infection [30] . In one study, 93% and 70% had 

Extensive research has been conducted into identifying epitopes to effectively measure T-114 cell responses, including a large study of overlapping peptides spanning the entire SARS-CoV-2 115 proteome [33]. Spike protein epitope pools are the most immunogenic stimuli [16, 34] . In a study of second generation pools, associated with increased activity and lower complexity for measuring Tdevelopment of effective vaccines is a global public health priority, with multiple candidates already 124 approved or authorised for use [12] . At the time of writing, randomised controlled trials of approved 125 vaccines have reported significant protection from severe disease [37] [38] [39] [40] . However, efficacy could 126 be affected by variants of concern [41] meaning updates to vaccines may be required. 

The generation of T-cell memory to protect against tuberculosis

Persistence of SARS-CoV-2-specific B and T cell 343 responses in convalescent COVID-19 patients 6-8 months after the infection

Rapid induction of antigen-specific CD4+ T cells guides 397 coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination

Fourth-generation QuantiFERON-TB Gold 48

Comparison between new QuantiFERON® TB Gold Plus and existing IGRAs in 402 active pulmonary tuberculosis

Tube and T-SPOT.TB on active tuberculosis in Japan

interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort 410 study

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro 421 respond to SARS-CoV-2

the novel tuberculosis vaccine M72/AS01 in South African adults

Final analysis of a trial of M72/AS01E vaccine to 428 prevent tuberculosis

Safety and immunogenicity of the M72/AS01E candidate tuberculosis 431 vaccine in adults with tuberculosis: A phase II randomised study